Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based VP’ operating in the Life Science space. If you think a VP’ is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Steve Lemon
VP, Engineering of 23andMe
Steve joined 23andMe in 2010 and is responsible for product and engineering. Prior to 23andMe, Steve was VP of engineering at Loopt and co-founder and VP of technology at Glimpse.com (acquired by TheFind.com). Earlier Steve served as the VP of engineering for Consumer Products and Solutions at Symantec and headed the engineering team at Cendura (acquired by CA), growing development and QA teams in both the U.S. and India. He also served as the SVP and GM of the Internet Portal Division for Healtheon/WebMD (IPO: HLTH), where he operated worldwide engineering and business teams and drove M&A technology integration.
Follow Steve Lemon:
About 23andMe, 23andMe: 23andMe is a DNA testing technology company that enables its users to access their ancestry, genealogy, and inherited traits.
Joyce Tung
Vice President, Research of 23andMe
Joyce Tung joined 23andMe in 2007. She has contributed to several of 23andMe’s research publications, and currently develops and manages research projects. she was a National Science Foundation Graduate Research Fellow in the lab of Dr. Renee Reijo Pera. At the University of California, San Francisco she focused on the genetics of egg and sperm development and human fertility. Joyce Tung returned to Stanford University for postdoctoral research in the lab of Dr. Gregory Barsh, where she studied the genetics of human and mouse pigmentation.
Follow Joyce Tung:
About 23andMe: 23andMe is a DNA testing technology company that enables its users to access their ancestry, genealogy, and inherited traits.
William H. King, IV
Senior Vice President, Strategic Development of Danaher
Mr. King is the Senior Vice President, Strategic Development for Danaher Corporation. Mr. King and his team drive market development, deal sourcing and commercial diligence at Danaher, thus co-owning the M&A process at Danaher with Mr. Daniel Raskas and the Corporate Development team. In addition, he and his team hold responsibility for the strategic planning process, tools and training. Mr. King joined Danaher in 1998 and has held positions as Managing Director of the Special Purpose Systems Motion Control Group, as well as Vice President of Sales and Marketing for the Motion Control Group. Prior to joining Danaher, he held positions of increasing responsibility in live production and logistics for Perdue, Inc. Mr. King has an MBA from Harvard Business School and a BS in Economics from University of Maryland.
Follow William H. King, IV:
About Danaher: Danaher is a global science and technology innovator committed to helping their customers solve complex challenges and improve quality.
Joakim Weidemanis
Group Executive/VP Product Identification Platform of Danaher
Joakim Weidemanis has been Vice President and Group Executive of Danaher Corp. since March 2014. Joakim Weidemanis served as Managing Director of Elster Metering Limited. He served as the Head of Product Inspection at Mettler-Toledo International Inc., since January 2006. From August 2005 to January 2006, he served as Head of Business Development of the Product Inspection Division. He held various management positions at ABB, including from July 2000 to August 2005 when he served as President of the North American water metering systems business and from early 2004 as the Head of the global water metering division that became Elster Water Metering Systems.
Follow Joakim Weidemanis:
About Danaher, Danaher: Danaher is a global science and technology innovator committed to helping their customers solve complex challenges and improve quality.
Colette Hastings Featherly
Senior Vice President of Oxford Finance LLC
Featherly has over 12 years of experience in the financial services industry, and has been part of the Oxford team since 2010. She is responsible for Oxford’s capital raising, strategic planning and investor relations activities. Prior to joining Oxford, she worked at Dymas Capital Management, a middle market lending affiliate of Cerberus Capital Management. Previously, she held positions at American Capital and CIBC World Markets. Ms. Featherly holds a B.S. in Commerce from the McIntire School of Commerce at the University of Virginia, and an M.B.A. from the Kellogg School of Management at Northwestern University.
Follow Colette Hastings Featherly:
About Oxford Finance LLC, Oxford Finance LLC: Oxford Finance delivers flexible financial solutions to healthcare and life sciences companies worldwide.
Earl May
Vice President of Lead Discovery of Civetta Therapeutics
Earl May is the Vice President of Lead Discovery at Civetta Therapeutics. He is a former Senior Director Biophysics at Warp Drive Bio, Inc. Mr. May graduated from the University of Maryland Baltimore County with a BA in Biochemistry and received an MPhil and Ph.D.in Molecular Biophysics and Biochemistry at Yale University.
Follow Earl May:
About Civetta Therapeutics: Civetta Therapeutics is a cancer therapeutics company to advance new medicines through small molecule targeting of beta-propeller domains.
Andrew Cook
Vice President and Head of Chemistry of Civetta Therapeutics
Andrew Cook is the Vice President and Head of Chemistry at Civetta Therapeutics. He was an Associate Director and Director of Medicinal Chemistry at H3 Biomedicine. Mr. Cook graduated from Imperial College London with a Ph.D. in Organic Chemistry and earned a BS in Chemistry at the University of Nottingham.
Follow Andrew Cook:
About Civetta Therapeutics: Civetta Therapeutics is a cancer therapeutics company to advance new medicines through small molecule targeting of beta-propeller domains.
Hamid Rategh
Vice President Engineering of Genapsys
Hamid is VP Engineering at GenapSys, joining back in 2012. Hamid has had a successful career developing a wide range of products, from RFICs to adaptive equalizers for optical communication and Mixed-Signal Memory interface products. Prior to joining GenapSys, Hamid was Senior Director of Engineering at Inphi, who acquired his team and product from Scintera Networks. Hamid also cofounded and served as VP of Engineering of Tavanza which was later acquired by Celeritek in 2002 and subsequently by Anadigics in 2003. Hamid holds a PhD in Electrical Engineering from Stanford University, and an MS in Biomedical Engineering from Case Western Reserve University. He earned his BS in Electrical Engineering from Sharif University of Technology.
Follow Hamid Rategh:
About Genapsys: Transform the human condition by building a scalable, affordable genomic sequencing ecosystem that will support research and diagnostics
Vadim Pinskiy
Vice President of Research and Development of Nanotronics Imaging
Vadim Pinskiy is the vice president of research and development at Nanotronics, where he oversees product development, short-term R&D, and long-term development of AI platforms. Vadim completed his doctorate work in neuroscience, focused on mouse neuroanatomy using high throughput whole slide imaging and advanced tracing techniques. Previously, he earned his master’s in biomedical engineering from Cornell University and his bachelor’s and master’s in electrical and biomedical from the Stevens Institute of Technology. Vadim is interested in applying advanced AI methods and systems to solving practical problems in biological and product manufacturing.
Follow Vadim Pinskiy:
About Nanotronics Imaging: Nanotronics Imaging is a microscopy and software company delivering rapid testing and analysis solutions.
Gurmeet Lamba
VP Engineering of Fetch Robotics
VP Engineering at Fetch Robotics – Autonomous Mobile Robotics. Previously COO & GM at Sentient Technologies – Artificial Intelligence (sold to Cognizant, Evolv). Also VP of Engineering at Sentient, executive engineering/product roles at Riverbed, Opnet (sold to Riverbed), Clarus Systems (sold to Opnet), head of engineering for Avaya’s Unified Communications BU, Bell Labs. Recipient of the Bell Labs President’s award). Attended IIT-Delhi (B.Tech, EE/Robotics), University of Florida (MS, EE/Robotics) and Stanford University (Executive Mgmt Program). Gurmeet is also an avid ceramics artist, and serves on the board of the Palo Alto Art Center Foundation.
Follow Gurmeet Lamba:
About Fetch Robotics, Sentient Technologies: Fetch Robotics provides the market’s only cloud-driven Autonomous Mobile Robot (AMR) solution for warehousing intralogistics environments.
David Fortes
Vice President of Operations of Fetch Robotics
David Fortes is the vice president of operations at Fetch Robotics.
Follow David Fortes:
About Fetch Robotics: Fetch Robotics provides the market’s only cloud-driven Autonomous Mobile Robot (AMR) solution for warehousing intralogistics environments.
Malaikannan Sankarasubbu
VP, AI Research of Saama
Follow Malaikannan Sankarasubbu:
About Saama: Saama is the number one AI-powered clinical analytics cloud platform company delivering actionable business insights for life sciences.
Peter Eggleston
SVP, US Commercial Products of Aptus Health
Early stage and small company product marketing and business development expert with 20+ years start-up experience in B-B & B-B-C SaaS/Cloud solutions.
Follow Peter Eggleston:
About Aptus Health: Aptus Health provides digital health engagement solutions for healthcare providers and patients.
Heow Tan
Vice President of Technical Operations of Collegium Pharmaceutical
Heow Tan has worked in the pharmaceutical industry for 25 years. He joined Collegium Pharmaceutical in 2006. He is responsible for CMC Product Development and Manufacturing activities. His experience in CMC includes working with oral, semi-solid and parenteral products, and successfully taking a product from pre-clinical to FDA and European approval. Prior to Collegium, he worked at Praecis Pharmaceuticals Inc., Waltham, Massachusetts as Vice President of Industrial Operations and Development;, He has also served as the Director of Manufacturing Operations for SciClone Pharmaceuticals Incorporated, San Mateo, California. Heow started his career in the Pharmaceutical industry working for Syntex Laboratories in Palo Alto, California, serving as the Manager of Manufacturing Engineering and Manager of Materials Control. He obtained his M.S. in Engineering from the Ohio State University, Ohio, and his M.B.A. from the University of Santa Clara, California.
Follow Heow Tan:
About Collegium Pharmaceutical: Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain.
Alison Fleming
EVP ,Product Development & Chief Technology Officer of Collegium Pharmaceutical
Alison Fleming was appointed Chief Technology Officer in 2017. Alison Fleming first joined Collegium Pharmaceutical in 2002, shortly after completing her Ph.D. in the School of Chemical and Biomolecular Engineering at Cornell University. Prior to joining Collegium, her academic research focused on implantable drug delivery systems for cancer therapy. Alison Fleming is an inventor on several United States Patents and pending patent applications and has authored numerous scientific publications and poster presentations in the field of novel drug delivery systems. In 2001 she was the recipient of the Jorge Heller Journal of Controlled Release Outstanding Paper Award. She received her B.S. degree in Chemical Engineering from the University of Massachusetts, Amherst.
Follow Alison Fleming:
About Collegium Pharmaceutical: Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain.
Richard Malamut
EVP & Chief Medical Officer of Collegium Pharmaceutical
Richard Malamut joined Collegium Pharmaceutical in April 2019 as Chief Medical Officer. Most recently, Richard Malamut served as Chief Medical Officer, Head of Research and Development and Senior Vice President for Braeburn Pharmaceuticals. Prior to joining Braeburn, he was Chief Medical Officer at Avanir Pharmaceuticals and was Senior Vice President of Global Clinical Development at Teva Pharmaceuticals Industries Ltd where he was responsible for Pain, Neuropsychiatry, Oncology and New Therapeutic Entities. He also previously held roles of increasing responsibility focusing on early clinical development and translational medicine in neurology and analgesia at Bristol-Myers Squibb and AstraZeneca. Richard Malamut earned his medical degree from Hahnemann University and completed both a residency in neurology and a fellowship in neuromuscular disease. He worked as a board-certified academic and clinical neurologist for 17 years and has more than 50 publications in the fields of pain medicine, neuromuscular disease, autonomic disease and neurodegenerative disease.
Follow Richard Malamut:
About Collegium Pharmaceutical: Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain.
Scott Dreyer
EVP & Chief Commercial Officer of Collegium Pharmaceutical
Scott Dreyer was appointed Executive Vice President and Chief Commercial Officer in July 2018. Scott Dreyer joined Collegium in January 2018 as Senior Vice President of Sales, Marketing, Commercial Capabilities and Training. He has over 25 years of commercial experience across sales, marketing, commercial operations and strategic planning, all within the biopharma industry. Most recently, Scott Dreyer was Senior Vice President, Marketing and Commercial Operations for The Medicines Company. Prior to joining The Medicines Company, he was Vice President and Chief Marketing Officer-US at Biogen. Prior to Biogen, Scott Dreyer held various commercial leadership positions of increasing responsibility at Merck & Co including Vice President-US Hospital and Oncology Sales and Commercial Operations, Vice President-US Primary Care Sales, Executive Director US Regional Marketing Leader – Neuroscience, Executive Director Customer Marketing and Solutions, Sr. Director of Strategic Planning and Director of Cardiovascular Marketing. Throughout his career, he has been involved in the commercialization of over 35 products across more than 15 therapeutic areas and launched over 20 products. Scott Dreyer received his B.S. degree in Biology from Messiah College in Grantham, PA.
Follow Scott Dreyer:
About Collegium Pharmaceutical: Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain.
Patrick Lindsay
Executive Vice President of United Biosource Corporation
Patrick Lindsay serves as President of UBC, guiding the company’s mission, vision, values, and strategic imperatives. He is responsible for clinical operations, business growth strategy, sales and marketing, and acquisition support. Patrick served as one of the early developers of the organization, which grew out of a passion for innovation and commitment to working with pharmaceutical and biotech organizations in providing safety, efficacy, and value of pharmaceutical and medical products. Patrick has been a leader in the healthcare and pharmaceutical services industry for more than 25 years. During his career, Mr. Lindsay has held senior management positions in such diverse areas as clinical stage operations, data management, biostatistics, information technology, marketing, and business development. He earned his Bachelor of Science in management from Rosemont College in Pennsylvania. Patrick is unconditionally focused on establishing high-level customer relationships and partnering with customers to match UBC service offerings to their research development projects, from both strategic and execution perspectives. Patrick was featured on the cover of the December 2013 edition of Pharmaceutical Executive: Pharma’s Life Partner: An Interview with United BioSource’s Patrick Lindsay.
Follow Patrick Lindsay:
About United Biosource Corporation: United BioSource is a medical and scientific affairs company developing and commercializing products for life science companies worldwide.
Annette Stemhagen
Senior Vice President, Safety, Epidemiology, Registries & Risk Management of United Biosource Corporation
Annette Stemhagen, DrPH, FISPE, provides strategic consultative services to pharmaceutical and biotechnology clients in epidemiology, safety surveillance, and risk management. In addition, she assists other UBC groups in developing and implementing creative and innovative study design solutions to meet client needs. Dr. Stemhagen has more than 25 years of public health epidemiological research experience, including 15 years in safety surveillance of pharmaceutical, biotech, and vaccine products. Her specific expertise is in the design, implementation, and analysis of epidemiologic studies, registries, large streamlined safety studies, and actual use and observational studies for products in Phase IIIb and postapproval. Further, Dr. Stemhagen has designed and evaluated risk assessment studies, including more than 50 regulatory-mandated long-term safety studies. She has also developed Risk Evaluation and Mitigation Strategies (REMS) risk minimization programs and risk management evaluation studies. Dr. Stemhagen received her undergraduate degree from the University of Pennsylvania, and her master’s and doctoral degrees from the University of Pittsburgh Graduate School of Public Health in Epidemiology. She holds adjunct faculty appointments at both the University of Pennsylvania School of Medicine Center for Epidemiology and Biostatistics and the Temple University School of Pharmacy. Dr. Stemhagen is a Fellow of the International Society for Pharmacoepidemiology and is active in the Drug Information Association. In 2004, she was appointed as the industry representative to the FDA Drug Safety and Risk Management Advisory Committee.
Follow Annette Stemhagen:
About United Biosource Corporation: United BioSource is a medical and scientific affairs company developing and commercializing products for life science companies worldwide.
Gene Hung
Co-founder and Senior Vice President of XinThera
Gene Hung is a Co-founder and Senior Vice President at Xinthera Inc.
Follow Gene Hung:
About XinThera: XinThera is a drug discovery company focused on building small molecule oncology and immunology pipeline.
Arthur Levin
Executive Vice President, Research & Development of Avidity Biosciences
Arthur A. Levin, Ph.D., is miRagen’s Executive Vice President of Research and Development. Dr. Levin is a drug development veteran having spent more than 30 years in the pharmaceutical industry, of which more than 15 years were in the area of research and development of RNA-targeting therapeutics. He is a recognized world expert on the preclinical and clinical development of oligonucleotide-based therapeutics. Prior to joining miRagen Therapeutics, Dr. Levin was Chief Development Officer of Santaris Pharma A/S, where he led the efforts on the first microRNA-targeting therapeutic in Phase 2 clinical trials, miravirsen. Before joining Santaris Pharma, Dr. Levin consulted for leading biotechnology companies, conducting research and development in RNA-based therapies such as mRNA, microRNA, and siRNA.Prior to consulting, Dr. Levin was Senior Vice President of Development at Isis Pharmaceuticals, where he was responsible for the drug development of Isis’ products across a range of therapeutic areas. His expertise was instrumental in advancing more than a dozen oligonucleotide drugs from basic research to clinical development in areas such as neuromuscular diseases, infectious diseases, metabolic disorders, cardiovascular disease, and cancer. He joined Isis from Hoffmann-La Roche Inc., where he was Research Leader. Dr. Levin holds a Ph.D. in Toxicology from the University of Rochester School of Medicine and Dentistry, New York, and a B.S. in Biology from Muhlenberg College.He completed his post-doctoral work at the Chemical Industry Institute of Toxicology in Research Triangle, North Carolina. He was the recipient of the Scala Award for Industrial Toxicology and is the author of more than 50 papers and book chapters.
Follow Arthur Levin:
About Avidity Biosciences, Avidity Biosciences: Avidity Biosciences is a biotech company that delivers nucleic acid therapeutics against genetic drivers of disease.
Andy Geall
Vice President of Formulations and Chemistry of Avidity Biosciences
Andy Geall is the VP of formulations and chemistry at Avidity Biosciences.
Follow Andy Geall:
About Avidity Biosciences: Avidity Biosciences is a biotech company that delivers nucleic acid therapeutics against genetic drivers of disease.
Brian Maples
VP/Head of Data Science of Prealize Health
Brian Maples leads the company’s development and execution of cutting edge machine learning methods applied to large and diverse member data sets. His work yields precise identification of members who are most at risk for as yet unidentified future high cost events. Prior to joining Prealize, Brian was a Data Scientist at Nuna Health, where he designed and developed machine learning and analytics products and capabilities in the healthcare space. He has also been the lead inventor at Ionian Technologies, a diagnostics startup that was subsequently acquired by Alere. While a PhD student at Stanford, Brian developed a machine learning method for large medical genetics data sets that is currently being privately licensed. Brian received both his PhD in Biomedical Informatics and MS in Statistics from Stanford University, and a BA in Science and Management from Claremont McKenna College.
Follow Brian Maples:
About Prealize Health: Prealize Health uses machine learning to transform healthcare from reactive to proactive.
Kathryn Fink
Vice President, Global Human Resources of Stryker
M. Kathryn (Katy) Fink was named Vice President, Global Human Resources, in January 2016. Ms. Fink is responsible for all human resources policies, practices, planning, direction and activities, including Talent Acquisition, Talent Development, Total Rewards and HR Shared Services. Ms. Fink began her career with Stryker in 2013 as Vice President, Talent Management and was promoted in 2015 to Vice President, Human Resources, MedSurg and Neurotechnology Group. Prior to joining Stryker, she held a number of HR roles of increasing scope and complexity at Cintas Corporation, Ethicon Endo-Surgery, a division of Johnson & Johnson. Ms. Fink holds a Bachelor of Science degree from Kenyon College and Master’s degree in human resource management (HRM) at Rutgers’ School of Management and Labor Relations.
Follow Kathryn Fink:
About Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
Yin Becker
Vice President, Chief Corporate Affairs Officer of Stryker
Follow Yin Becker:
About Stryker, Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
Glenn S. Boehnlein
Chief Financial Officer & Vice President of Stryker
Follow Glenn S. Boehnlein:
About Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
Eugene A. Gregerson
Vice President R&D of Stryker
Eugene A. Gregerson is the Vice President R&D at Stryker Spine.
Follow Eugene A. Gregerson:
About Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
Elizabeth A. Staub
Vice President, Regulatory Affairs and Quality Assurance of Stryker
Elizabeth A. Staub was named Vice President, Regulatory Affairs and Quality Assurance, in April 2006. Ms. Staub is responsible for overseeing Stryker’s compliance with worldwide product quality and regulatory requirements, including FDA and other regulatory bodies. Ms. Staub began her career with Stryker in April 1989 and held a number of quality, regulatory and operational positions within the Company’s Orthopaedics division, including Manager, Quality Assurance; Team Leader for the packaging cell; Manufacturing Team Leader for the external support cell; Director of the Knee Steering Team; Vice President, Quality Assurance, Regulatory Compliance and Clinical Research; and Director of the Business Process Excellence Project. She then served as Director, Regulatory Affairs and Quality Assurance, for the Company from 2005 to 2006. Prior to joining Stryker, Ms. Staub spent six years with Baxter Healthcare in a variety of quality assurance positions. Ms. Staub holds a B.S. in Medical Technology from York College of Pennsylvania.
Follow Elizabeth A. Staub:
About Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
Jeanne M. Blondia
VP & Treasurer of Stryker
Follow Jeanne M. Blondia:
About Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
Irene B. Corbe
Vice President, Internal Audit of Stryker
Irene B. Corbe joined Stryker in April 2014 as Vice President, Internal Audit. Ms. Corbe reports to the Audit Committee of Stryker’s Board of Directors. In this role, Irene oversees Stryker’s financial audit activity which is a critical component of the corporate governance structure. Irene joined Stryker with 25 years of experience in internal audit, finance and accounting in various roles of increasing responsibilities. Most recently, Ms. Corbe was the Vice President, Internal Audit at Whirlpool Corporation. Ms. Corbe received her Masters of Business Administration from Oakland University and her undergraduate degree in business administration from the University of Michigan. She is also a Certified Public Accountant.
Follow Irene B. Corbe:
About Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
Bronwen R. Taylor
Vice President, Risk Management of Stryker
Bronwen Taylor was named Vice President, Compliance and Risk Management in August 2013. Ms. Taylor is responsible for the coordination of Stryker’s compliance programs and liability avoidance efforts worldwide. Ms. Taylor joined Stryker in March 2000 as Chief Financial Officer for Stryker South Pacific. She subsequently served as Vice President and Chief Financial Officer and as Director, Operations, of Stryker South Pacific. Ms. Taylor relocated to Kalamazoo in January 2006 to become Stryker’s first Chief Compliance Officer. In 2007 Ms. Taylor was promoted to Vice President of Internal Audit and Compliance and in 2010 she moved to Newbury, UK to become Vice President, Chief Financial Officer for our European operations. Prior to joining Stryker, Ms. Taylor held senior finance positions in financial services and global mining companies in Australia. She started her career as an accountant with Coopers & Lybrand (now PricewaterhouseCoopers) in Australia and held various positions in the Australian and United Kingdom firms. Ms. Taylor holds a B.B.A. from the Queensland University of Technology, Australia, and an M.B.A. from Monash University, Victoria, Australia. She is also a fellow of the Institute of Chartered Accountants in Australia.
Follow Bronwen R. Taylor:
About Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
William E. Berry Jr.
Vice President, Corporate Controller of Stryker
Follow William E. Berry Jr.:
About Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
David G. Furgason
Vice President, Tax of Stryker
Follow David G. Furgason:
About Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
John Casey
Co-Founder, Vice President, Head of Business Development of Senda Biosciences
John is the Co-Founder, Vice President, and Head of Business Development of Senda Biosciences. Before that, he joined Flagship Pioneering in 2015 as an associate after completing the VentureLabs Fellows program. At Flagship, John works as part of a venture creation team, exploring innovative ideas and opportunities, and developing critical scientific and business components that will lead to the firm’s next breakthrough startups. Before joining Flagship, John earned his doctorate in biological engineering in Angela Belcher’s lab at MIT, where he designed and developed thermostable de novo enzymes on viral capsid proteins. His work led to a collaboration with the pharmaceutical industry to develop cleaner, more versatile manufacturing processes. John was an active contributor to Boston’s entrepreneurial community while a graduate student. As associate director for MIT’s $100K Entrepreneurship Competition, he partnered with local and national businesses to raise the competition’s six-figure annual budget. He developed a new prototyping contest with increased resources and direct support for student entrepreneurs. He subsequently served as Chair of the $100K’s board of directors. Additionally, John was a communication fellow in the Biological Engineering Department and served as the biotechnology editor for the MIT Entrepreneurship Review. John received his B.S. in biological engineering from Louisiana State University, where he was a Goldwater Scholar and named the top graduating student in his class. His thesis research explored site-specific oligonucleotide modifications. John was active in LSU’s Student Government, president of the campus Habitat for Humanity chapter, and a co-founder and president of an organization for Mandarin Chinese speakers.
Follow John Casey:
About Senda Biosciences: Senda Biosciences is a therapeutics platform company leveraging unprecedented insights into the molecular connections between humans.
Andrew Scott
Vice President of Corporate Development of Citius Pharmaceuticals
Follow Andrew Scott:
About Citius Pharmaceuticals: Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products.
Gary Talarico
Executive Vice President of Operations of Citius Pharmaceuticals
Gary Talarico has served as EVP, Operations since March 2016. Gary has successfully built and led all commercial activities for a number of start-up companies. Most recently he was a founder, partner and Executive Vice President of Leonard Meron Biosciences; he was instrumental in acquiring its lead product. Previously, Gary served as Senior Vice President of Triax Pharmaceuticals, from its founding to the sale of its assets. Gary was a founder and Executive Vice President of Sales and Marketing for Reliant Pharmaceuticals, LLC; Reliant was later sold to GlaxoSmithKline plc. Before Reliant, Gary was Executive Vice President of Business Development for Ventiv Health. His earlier experience included Vice President of Sales for Medicis Pharmaceutical at its initial start-up, and Director of Sales at ICN Pharmaceuticals, Inc. Gary is a graduate of Lewis University.
Follow Gary Talarico:
About Citius Pharmaceuticals: Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products.
Alan Lader
Vice President of Clinical Operations of Citius Pharmaceuticals
Alan Lader joined Citius Pharmaceuticals as Vice President of Clinical Operations in 2016
Follow Alan Lader:
About Citius Pharmaceuticals: Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products.
Duane Valz
VP & General Counsel of Insitro
Duane has counseled a wide variety of privately held and public companies on law, technology and business matters. Duane is presently VP & General Counsel of insitro, a company applying machine learning and high throughput biology toward disease target identification and drug discovery. Immediately prior to insitro, Duane was VP & General Counsel at Zymergen, a company applying machine learning and high throughput biology to improving microbial production of in market and novel industrial chemicals. Duane was previously a member of the Patent Team at Google, where he led strategic IP initiatives bearing on mobile, cloud, web and open source technologies. He was also previously Associate General Counsel in charge of patent development at Yahoo! Duane began his career at Howard Rice Nemerovski Canady Falk & Rabkin (now combined with Arnold & Porter LLP). He holds BA and JD degrees from the University of California, Berkeley.
Follow Duane Valz:
About Insitro: Insitro is a drug discovery and development startup that utilizes machine learning and biology to transform drug discovery.
Elizabeth Buck
Founder, Executive Vice President of Black Diamond Therapeutics
Elizabeth Buck is co-founder and Executive VP, Discovery & Translational Sciences for Black Diamond Therapeutics. Dr. Buck was instrumental in developing Black Diamond’s MAPing platform though which she made critical discoveries leading our understanding of the properties of allosteric mutations in oncogene activation. Dr. Buck has over 15 years of experience in oncology therapeutics in biotechnology and large pharma industries. Her expertise and productivity are evidenced by more than 40 peer reviewed publications and patents. Prior to joining Black Diamond, Dr. Buck was Assistant Director of Advanced Preclinical Pharmacology at OSI Pharmaceuticals, where she led discovery and translational research to advance a series of oncology programs to clinical development. During this role Dr. Buck managed multidisciplinary global teams and spearheaded major academic collaborations to progress programs to IND. Dr. Buck received her undergraduate degree in physics from the University of New Hampshire, Ph.D. in cellular and molecular biology from New York University / Mount Sinai School of Medicine, and completed postdoctoral work with Jim Wells at Sunesis Pharmaceuticals.
Follow Elizabeth Buck:
About Black Diamond Therapeutics: Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule.
Lara Hashimoto
SVP – Chief Business Officer of SOPHiA GENETICS
Growing up in Canada, Lara developed an early interest in understanding the role of genetics in common diseases. This took her from studying the genetics of Multiple Sclerosis at the University of Western Ontario to joining the Wellcome Trust Centre for Human Genetics at the University of Oxford, UK. Lara joined SOPHiA GENETICS in 2020, but first joined the industry 20 years ago as a Scientist at Roche Pharma based in Basel, Switzerland. She has held several positions spanning Pharma clinical drug development, business analytics, and strategic marketing in the global organization as well as sales and operational marketing positions in the Canadian affiliate. In 2009, Lara moved to Roche Molecular Diagnostics in California as the Lifecycle Leader responsible for the Genomics and Oncology IVD product portfolio and pipeline, launching several companion diagnostics globally. Lara then became the General Manager of Roche Diagnostics New Zealand Ltd where she grew sales above the market for 4 consecutive years. Returning to the Bay Area, Lara then joined the newly formed Roche Sequencing Solutions team where she was the VP responsible for Non-Invasive Prenatal Testing and the Nanopore Sequencer before being appointed Chief Commercial Officer.
Follow Lara Hashimoto:
About SOPHiA GENETICS: SOPHiA GENETICS is a biotechnology firm that aims to support healthcare professionals by maximizing the power of data-driven medicine.
Deborah (Deb) Autor
Senior Vice President, Head of Strategic Global Quality & Regulatory Policy of Mylan
Deb (Deborah) Autor is Mylan’s Senior Vice President, Head of Strategic Global Quality & Regulatory Policy. Autor joined Mylan after more than a decade of service at the FDA. Deb is a transformative innovator with a unique, multifaceted view of the biopharmaceutical industry built on decades of domestic and global public and private sector experience. Autor’s expertise is highly respected in the industry, with a vast personal network and many board memberships.
Follow Deborah (Deb) Autor:
About Mylan: From 1961-2020, Mylan offered a broad portfolio of generic and specialty pharmaceutical products.
Jonathan Collins
Vice President, Manager & Head of eCommerce of Mylan
Jonathan Collins is Vice President & Head of eCommerce at Mylan. He is Member of the Board of Directors at Carlisle.
Follow Jonathan Collins:
About Mylan: From 1961-2020, Mylan offered a broad portfolio of generic and specialty pharmaceutical products.
Michael Klichinsky
Co-Founder & VP, Discovery Research of Carisma Therapeutics
Michael is a PhD Candidate in the Department of Systems Pharmacology and Translational Therapeutics at the University of Pennsylvania Perelman School of Medicine.He developed CARMA for his doctoral thesis under the co-mentorship of Saar Gill, MD, PhD and Carl June, MD. Michael previously earned a Doctor of Pharmacy degree from the University of Sciences in Philadelphia, graduating Magna Cum Laude. Michael’s scientific expertise is in the field of genetic engineering and immunology, with a focus on chimeric antigen receptor technologies.
Follow Michael Klichinsky:
About Carisma Therapeutics: Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Craig Roberts
AVP, Vaccines, Center for Observational and Real-World Evidence of Merck
Craig Roberts is currently Associate Vice President for the Center for Observational and Real-world Evidence (CORE) Vaccines Product Line within Merck Research Labs. In this role he leads a research team that designs and conducts observational research studies to characterize the public health and economic burden of vaccine preventable diseases globally. The team develops data to simulate the impact of Merck vaccines on disease, and applies these data to communicate the value of vaccines to public health decision makers. Prior to joining Merck, Dr Roberts was leading the health economic and outcomes research team supporting Global Vaccines and Consumer Products for Pfizer Inc. During his tenure at Pfizer, he made significant contributions defining the value proposition of several key products globally, including Zithromax, Vfend, Norvasc, Lipitor, Caduet, and Prevenar 13. Prior to joining Pfizer, Dr. Roberts led outcomes research operations at NDCHealth, where he was responsible for the design, conduct, and publication of analyses from large US healthcare databases. Dr. Roberts has co-authored numerous publications in peer-reviewed journals including Vaccine, Stroke, CHEST, Value in Health, and Pharmacoeconomics. He earned his PharmD and MPA degrees from the University of Kentucky, received an MBA from New York University, and completed a fellowship in health economics through GlaxoSmithKline and Thomas Jefferson University in Philadelphia.
Follow Craig Roberts:
About Merck: Merck is a pharmaceutical and chemical enterprise that develops prescription drugs and over-the-counter products.
Steven Battista
Vice President of Anzu Partners
Steven Battista is the Vice President at Anzu Partners.
Follow Steven Battista:
About Anzu Partners: Anzu Partners is an investment firm that invests in industrial and life science technology companies.
Jonathan Morris
VP & GM US Healthcare of IQVIA
Jonathan Morris is the VP & GM US Healthcare at IQVIA.
Follow Jonathan Morris:
About COTA Healthcare, Inteliquet, Inc., IQVIA, Life Sciences Greenhouse of Pennsylvania: IQVIA is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry.
Patrick Daly
Global Vice President & General Manager of IQVIA
Mr. Daly has over 20 years of experience in medical device sales, marketing, international marketing and leadership positions throughout the Johnson & Johnson organization including Ethicon Endo-Surgery, Ethicon Products, J&J Medical Australia/New Zealand, J&J Medical Asia Pacific and Cohera Medical, Inc.® Within Johnson & Johnson, he held positions of increasing responsibility in marketing, international marketing and sales. He successfully launched a surgical technology business in Australia and created and implemented the first-ever regulatory review of safety and efficacy of that new technology by the Australian Government. He continued his Johnson & Johnson entrepreneurial-like career track as a marketing leader in J&J Medical Asia Pacific by creating and implementing training and development programs in China, India, Korea, Singapore, and the Philippines. Mr. Daly started Cohera Medical in January 2006 and led three successful funding rounds of over $57.8M in capital from private investors to facilitate Cohera Medical’s lead product TissuGlu® Surgical Adhesive through the FDA approval process for medical devices. Prior to joining Cohera Medical and Johnson & Johnson, Mr. Daly spent over four years on active duty in the U.S. Army as a field artillery officer serving around the world. A native of New York, he is a graduate of the U.S. Military Academy at West Point where he received a B.S. in Engineering with a concentration in Latin American Studies. He played varsity lacrosse during his four years at West Point and was an All-American. Mr. Daly serves on several Boards, including the Emerging Growth Company Council (EGCC) for the Advanced Medical Technology Association (AdvaMed), the Pittsburgh Technology Council and Girls Hope, a nonprofit that provides a well-balanced, nurturing home and quality education through college for academically capable girls. He is also a member of the Young Presidents Organization.
Follow Patrick Daly:
About IQVIA: IQVIA is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry.
Rajneesh Patil
Vice President, Digital Strategy & Innovation of IQVIA
Rajneesh Patil is the Vice President, Digital Strategy & Innovation at IQVIA.
Follow Rajneesh Patil:
About IQVIA: IQVIA is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry.
Christina Bodurow
Vice President, Strategic Operations, Data Science, Statistics, and Regulatory of IQVIA
Follow Christina Bodurow:
About IQVIA, IQVIA: IQVIA is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry.
Michael Laird
Vice President of Genentech
Vice President, Cell Culture & BioProcess Operations Genentech, Inc.
Follow Michael Laird:
About Genentech: Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients.
Ira Mellman
Vice President, Cancer Immunology of Genentech
Vice President of Cancer Immunology at Genentech.
Follow Ira Mellman:
About Genentech, University of California, San Francisco: Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients.
Michael Henry
Senior Vice President and General Manager of Consumer Genomics of Centrillion Technologies
Michael Henry is a Senior Vice President and General Manager of Consumer Genomics at Centrillion Biosciences, Inc. He is also an Advisor of Berkeley SkyDeck.
Follow Michael Henry:
About Centrillion Technologies: Centrillion Biosciences develops genomics and DNA analyses technology for personalized medicine, life sciences research, and bioinformatics.
Glenn McGall
SVP Technology of Centrillion Technologies
Glenn McGall is the SVP Technology at Centrillion Biosciences.
Follow Glenn McGall:
About Centrillion Technologies: Centrillion Biosciences develops genomics and DNA analyses technology for personalized medicine, life sciences research, and bioinformatics.
Jacob Graham
Co-Founder & VP QA/RA of Enzyme
Jacob is an 11 year veteran of the medical device industry, with a background in quality management, design assurance, and audit planning. He has helped commercially launch several Class II and III devices and has overseen multiple FDA and EU notified body audits. Prior to co-founding Enzyme he held quality management positions at Medtronic and Boston Scientific. Jacob has an MBA from Babson College and a BS in Engineering from Olin College. Additionally he has achieved several professional certifications in the life sciences, and is an ASQ Certified Biomedical Auditor and RAPS Regulatory Affairs Certified (US).
Follow Jacob Graham:
About Enzyme: Enzyme is building software to help life sciences companies with FDA approval and regulatory compliance.
Steve Moffatt
VP Hardware of Athelas
Follow Steve Moffatt:
About Athelas, Athelas: Athelas develops technology to monitor chronically ill patients in their homes.
Michael Pettigrew
VP, Asset Acquisition of BridgeBio Pharma
Michael Pettigrew is Director of Asset Acquisition at BridgeBio.
Follow Michael Pettigrew:
About BridgeBio Pharma: BridgeBio Pharma focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D.
Justin To
VP of Business Development and Operations, Gene Therapy of BridgeBio Pharma
Justin To is Associate Director of Portfolio Management at BridgeBio.
Follow Justin To:
About BridgeBio Pharma: BridgeBio Pharma focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D.
Yongwei Zhang
Group VP, CEO of Americas Region of BGI Group
Yongwei Zhang, Ph.D., serves as Executive Director of BGI Research, the R&D arm of BGI-Shenzhen, world’s largest genomics service company. He is also Chief Operating Officer of Complete Genomics (San Jose, CA), a wholly-owned subsidiary of BGI. Yongwei Zhang has over 20 years of experience in optics-based instruments and systems. He began his career in Quinta Technologies developing optically-assisted computer hard drives. Quinta was later acquired by Seagate. He was a Co-Founder of telecom component startup company iolon, Inc, which has raised ~$100million VC funding. He joined biotech startup Guava Technologies in 2005, where he held positions with increasing responsibilities. Guava was later acquired by Millipore, subsequently by Merck KGaA. As Head of New Product Introduction at Merck Life Science division, he helped to develop and manufacture several generations of Guava flowcytometry instruments and reagent kits, including the award-winning Muse Cell Analyzer. In 2013, he joined Complete Genomics as Sr. Director of Engineering, responsible for the development of NGS sequencing platform BGISEQ series. Yongwei Zhang is also a strong advocate for STEM education. He served as a Board Member of US nationally top-ranked Saratoga School Union District. Yongwei Zhang received his B. Eng in Precision Instruments and B.Sc. in Applied Mathematics from Tsinghua University in Beijing, M.S. in Computer Sciences, M.S. and Ph.D. in Mechanical Engineering from The Johns Hopkins University in Baltimore, MD.
Follow Yongwei Zhang:
About BGI Group: BGI Group is one of the world’s largest DNA sequencing service providers.
Mary Godwin
Vice President Operations of Nautilus Biotechnology
Follow Mary Godwin:
About Nautilus Biotechnology: Nautilus Biotechnology offers a high-throughput, low-cost platform for analyzing and quantifying the human proteome.
Marcelo Trevino
Global VP, Regulatory Affairs & Quality Assurance of Agendia
Marcelo Trevino serves as the Global Vice President of Regulatory Affairs and Quality Assurance at Agendia.
Follow Marcelo Trevino:
About Agendia: Agendia provides molecular diagnostics and personalized treatment plans for cancer patients.
Nick Macris
Vice President, Environment Sector of Precigen
Mr. Macris brings 15 years of business and technical experience in the natural product, industrial and specialty technical industries to Intrexon. Macris joins the company from Marrone Bio Innovations, an early-stage biopesticide company focused on natural product solutions for disease and pest management in plants and aquatic systems where he was Vice President of Business Development. Macris has worked in various roles at several other agricultural and environmental biotech companies, including business development at Purifics ES Inc., corporate development and mergers and acquisitions at FMC Corporation, and corporate level platform development as well as business development activities to establish a biopesticide portfolio at Rohm & Haas. Prior to pursuing his M.B.A., Macris worked in the specialty chemical division and the tape product engineering group at 3M Canada. Macris earned an M.E.Sc. in Chemical and Biochemical Engineering from the University of Western Ontario and an M.B.A. from the Richard Ivey Business School in London, Canada.
Follow Nick Macris:
About Precigen, Purifics ES Inc, Rohm & Haas: Precigen is a life sciences company researching and developing bio-therapeutic control systems to minimize toxicity.
Carol Spector Dingle
Vice President Technical Services of On Assignment
Carol Dingle has held executive-level positions in software development and IT operations for more than 18 years. As Vice President of Technical Services at On Assignment, Inc., she oversees the technical needs of an international staffing organization with multiple divisions across the United States and Europe. Prior to her current position, she was Vice President of Operations and Infrastructure at banking technology provider Digital Insight.
Follow Carol Spector Dingle:
About On Assignment: On Assignment is a provider of highly skilled, hard-to-find professionals in the growing technology, life sciences, and creative sectors.
Mary Lou Freathy
Vice President of Quality & Manufacturing of Arbor Pharmaceuticals
Mary Lou has more than 25 years of pharmaceutical experience in quality, regulatory affairs, and manufacturing compliance including over 10 years supporting the growth of life science companies. Mary Lou was previously Senior Vice President of Quality, Regulatory Affairs, and Chief Compliance Officer of G&W Laboratories. Prior to that, she held several executive managerial positions at Paddock Laboratories, Pliva, Inc., and Dey Laboratories where she started her pharmaceutical career. Mary Lou belongs to several professional societies including RAPS, PDA, ISPE, and ASQ. She holds a J.D. from the Empire School of Law, and a B.A. in Chemistry from the State University of New York. She is also a Certified Compliance Professional.
Follow Mary Lou Freathy:
About Arbor Pharmaceuticals: Arbor Pharmaceuticals is a specialty pharmaceutical company developing late-stage therapeutic products for common pediatric conditions.
Thom Rowland
Vice President, Commercial Operations of Arbor Pharmaceuticals
Thom Rowland is an industry veteran who started his career as a sales representative for UCB Pharmaceuticals. Thom later held various marketing positions with UCB prior to taking the position of head of marketing for Scandipharm. He played a lead role in turning the Scandipharm business around prior to its sale to Axcan Pharmaceuticals. Thom then served as a Vice President of Sales and Marketing for several business units at Solvay Pharmaceuticals where he was again instrumental in turning around an underperforming area. Thom was one of the founders of Ventrus Biosciences which completed a successful IPO in 2010.
Follow Thom Rowland:
About Arbor Pharmaceuticals, Axcan Pharmaceuticals, Solvay Pharmaceuticals, UCB: Arbor Pharmaceuticals is a specialty pharmaceutical company developing late-stage therapeutic products for common pediatric conditions.
Steven Caras
Vice President of Clinical Development of Arbor Pharmaceuticals
Dr. Steven Caras is a gastroenterologist and biomedical engineer. He has a Bachelors degree in Chemical Engineering from Arizona State University and Masters and Ph.D. degrees in Bioengineering from the University of Utah in Salt Lake City. Steve obtained his medical degree from the University of Miami. He did his residency training in internal medicine at Washington University in St. Louis and his gastroenterology fellowship at University of Virginia in Charlottesville. After his gastroenterology fellowship, Steve worked as a medical reviewer in the Cardio-Renal Division of FDA, where he was mainly involved in antihypertensive and antiarrhythmic drugs. Steve currently volunteers for a local chamber of commerce which evaluates pharmaceutical and medical device companies and provides these companies with essential development, regulatory, and business feedback. Steve is also an Adjunct Professor at the University of Georgia’s College of Pharmacy’s Regulatory Affairs and Clinical Trials Graduate Program.
Follow Steven Caras:
About Arbor Pharmaceuticals: Arbor Pharmaceuticals is a specialty pharmaceutical company developing late-stage therapeutic products for common pediatric conditions.
Serafim Batzoglou
SVP, Data of Seer
Follow Serafim Batzoglou:
About DNAnexus, Seer: Seer is a biotechnology company that offers tools and solutions related to the field of proteomics.
Weston Daniel
Vice President of Translational Research of Exicure
Weston Daniel is the Vice President of Translational Research at Exicure.
Follow Weston Daniel:
About Exicure: Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets.
Ryan Helon
SVP, Investments of Rev1 Ventures
Ryan J. Helon serves as Senior Vice President, Investments at TechColumbus, Investment Arm. Mr. Helon serves as Managing Director at Nationwide Mutual Capital. He leads Nationwide Mutual, including originating, executing, and managing investments. He also develops and implements strategies for Nationwide Mutual to leverage the resources of Nationwide to add value to Nationwide Mutual Capital portfolio companies. He also leads strategy development for Nationwide Mutual. Prior to his leadership role with Nationwide Mutual, Mr. Helon served as a Corporate Development Manager at Nationwide, where he led and participated in many transactions, including the CalFarm and Marítima acquisitions, the private equity investments in Teamstaff and Capital Professional Advisors and Nationwide Mutual’s $400 million issuance of surplus notes. Mr. Helon also jointly led the creation and development of the firm. Prior to Nationwide, he worked in corporate finance in the chemical industry, primarily on M&A transactions. Mr. Helon serves on the Boards at First Choice Solutions, Skybus, and The Columbus Council on World Affairs. Mr. Helon received an M.B.A. from The Ohio State University Fisher College of Business, where he graduated as salutatorian and graduated with a Bachelor’s degree in Finance and Economics, summa cum laude, also from The Ohio State University Fisher College of Business.
Follow Ryan Helon:
About Rev1 Ventures: Rev1 Ventures is an investor startup studio that combines capital and strategic services to help startups scale and corporates innovate.
Wayne Embree
EVP, Venture Acceleration & Investments of Rev1 Ventures
Wayne ensures that our Venture Development and Investment teams have everything they need to help entrepreneurs build great companies. After three decades of being an entrepreneur, investor, board member, and mentor, he has no intention of stopping now. Wayne has a BS in Natural Sciences from Western Oregon and an MS in Urban Planning from the University of Oregon. He takes his favorite quote, “When the going gets weird, the weird turn pro,” seriously.
Follow Wayne Embree:
About Rev1 Ventures: Rev1 Ventures is an investor startup studio that combines capital and strategic services to help startups scale and corporates innovate.
David Bergeron
SVP, Venture Acceleration & Development of Rev1 Ventures
David works with Rev1 clients on market validation. He helps entrepreneurs develop business plans that position startups to clear milestones and remove risk. While working in Silicon Valley, David helped entrepreneurs develop business plans for ideas and technologies emerging from academic and other institutions. Advances included new 3D flash memory from Stanford, an evolving novel new plasma etch technology from Cal Poly, and MEMS-based scanning electron microscopy from UC Berkley. David has BS degrees in both Physics and Mathematics from Georgetown University, plus as MS degree in Applied Mathematics from Georgetown University. David’s favorite book is Cosmos by Carl Sagan, and he wishes he had invented video games. So do we.
Follow David Bergeron:
About Rev1 Ventures: Rev1 Ventures is an investor startup studio that combines capital and strategic services to help startups scale and corporates innovate.
Mike McCann
VP, Corporate Partnerships of Rev1 Ventures
Mike McCann is An MBA from The Ohio State University, Mike also holds a BA in History. Here at Rev1, he’s helping our clients make history of their own. Mike leads two strategic programs that deliver expertise and talent to Rev1 clients. The Expert Network connects startups with quality professional services firms. Our growing set of talent initiatives and services help startups find the resources they need. An avid golfer, Mike admires caddies everywhere as great examples of entrepreneurship.
Follow Mike McCann:
About Rev1 Ventures: Rev1 Ventures is an investor startup studio that combines capital and strategic services to help startups scale and corporates innovate.
Aaron Kennington
Vice President of Engineering of Intellicyt
Follow Aaron Kennington:
About Intellicyt: IntelliCyt Corporation develops and markets high-throughput cell and bead-based screening solutions for the use of life sciences.
Joel Morales
EVP & Chief Financial Officer of Alvotech
Joel Morales is the EVP and Chief Financial Officer at Alvotech.
Follow Joel Morales:
About Alvotech: Setting a new standard in biosimilars
Vijay Jegan
SVP of Engineering & CTO of Tact.ai
Follow Vijay Jegan:
About Tact.ai: The customer engagement company for life sciences
Donna Dennis
Vice President of Nova Science Publishers
Follow Donna Dennis:
About Nova Science Publishers: A top academic publisher with high quality publications
Curt Weinstein
Vice President & General Manager of Corning
Follow Curt Weinstein:
About Corning: Corning is a manufacturer of building materials including glass, ceramic, related materials and technologies, and more.
Jeff Evenson
Executive Vice President & Chief Strategy Officer of Corning
Jeff Evenson is the Senior Vice President and Operations Chief of Staff for Corning, Inc. As a member of the 7-person Management Committee, Jeff has responsibilities including strategy implementation and special projects. Prior to joining Corning, Jeff was a senior sell-side analyst at Sanford Bernstein, where he was a consistent Institutional Investor All-Star in the Data Networking Sector. Prior to Corning, Jeff was a Partner at McKinsey & Company, where he was a leader in the technology strategy practice. During his career, Jeff has focused on strategy and finance for a broad range of technologies including data networking, smart grids, photonics, III-V semiconductors and drug discovery tools. Jeff holds an SB in Physics from MIT and a Ph.D. in Physics from Harvard, where he was a National Science Foundation Fellow. His thesis addressed the interaction of light and matter.
Follow Jeff Evenson:
About Corning: Corning is a manufacturer of building materials including glass, ceramic, related materials and technologies, and more.
Tony Tripeny
SVP Corporate Controller of Corning
Tony Tripeny became Corning’s chief financial officer in September 2015. As CFO, Tripeny is the chief steward of Corning’s financial health, overseeing the finance and Investor Relations functions. From April 2009 to August 2015, Tripeny was Senior Vice President, Corporate Controller and Principal Accounting Officer. In this role, he was responsible for the accounting, analytical services, business control, and tax functions and co-led the global finance organization. Tripeny joined Corning Cable Systems in 1985 as the corporate accounting manager. In March 1989, he moved to Texas to work in the Corning Cable Systems’ Keller facility as the plant controller. In January 1993, he was appointed equipment division controller. He relocated to Hickory in 1996 as the corporate controller. Tripeny was appointed to chief financial officer in July 2000 and added the additional responsibilities of group controller, Telecommunications, in February 2003. He was appointed to division vice president, Operations Controller in August 2004, and then named vice president, corporate controller, in October 2005. Tripeny received a bachelor’s degree in economics from the University of Pennsylvania’s Wharton School of Business. He is a member of the Financial Executives Institute and the Institute of Management Accounting.
Follow Tony Tripeny:
About Corning: Corning is a manufacturer of building materials including glass, ceramic, related materials and technologies, and more.
Martin J. Curran
Innovation Officer – Executive Vice President of Corning
Marty Curran was appointed Corning’s first innovation officer in August 2012. In this role, Curran manages a portfolio of programs to increase the probability of success for new business opportunities. The innovation office was created to build an entrepreneurial-focused organization that could operate across all business segments to identify and develop near-term revenue opportunities. Over time, expectation is to streamline the innovation process where appropriate and increase speed-to-market. Curran joined Corning in 1984 and has held a variety of roles in finance, manufacturing, and marketing. He has served as senior vice president, general manager for Corning Cable Systems Hardware and Equipment Operations in the Americas of which he was responsible for operations in Hickory, N.C.; Keller, Texas; Reynosa, Mexico; Shanghai, China and the Dominican Republic. Curran led efforts to grow Corning’s Connectivity business, including the first major fiber-to-the home offering with Verizon FiOS. He has also served as senior vice president and general manager for Corning Optical Fiber and has served as Chairman of US Conec, a Corning Connectivity joint venture with Fujikura and NTT-AT. Curran graduated from the University of Notre Dame with a bachelor’s degree in finance and received his master’s degree from the University of Virginia’s Colgate Darden Graduate School of Business.
Follow Martin J. Curran:
About Corning: Corning is a manufacturer of building materials including glass, ceramic, related materials and technologies, and more.
Martin J. Curran
Innovation Officer – Executive Vice President of Corning
Marty Curran was appointed Corning’s first innovation officer in August 2012. In this role, Curran manages a portfolio of programs to increase the probability of success for new business opportunities. The innovation office was created to build an entrepreneurial-focused organization that could operate across all business segments to identify and develop near-term revenue opportunities. Over time, expectation is to streamline the innovation process where appropriate and increase speed-to-market. Curran joined Corning in 1984 and has held a variety of roles in finance, manufacturing, and marketing. He has served as senior vice president, general manager for Corning Cable Systems Hardware and Equipment Operations in the Americas of which he was responsible for operations in Hickory, N.C.; Keller, Texas; Reynosa, Mexico; Shanghai, China and the Dominican Republic. Curran led efforts to grow Corning’s Connectivity business, including the first major fiber-to-the home offering with Verizon FiOS. He has also served as senior vice president and general manager for Corning Optical Fiber and has served as Chairman of US Conec, a Corning Connectivity joint venture with Fujikura and NTT-AT. Curran graduated from the University of Notre Dame with a bachelor’s degree in finance and received his master’s degree from the University of Virginia’s Colgate Darden Graduate School of Business.
Follow Martin J. Curran:
About Corning: Corning is a manufacturer of building materials including glass, ceramic, related materials and technologies, and more.
Hodges Mauri
Vice President, Finance and Administration, Chief Financial Officer and Treasurer of Catalyst Biosciences
Ms. Hodges joined Targacept in August 2000 and currently serves as Vice President, Finance and Administration, Chief Financial Officer and Treasurer. Ms. Hodges was previously Vice President, Human Resources and Corporate Systems and served as Controller for over thirteen years. Ms. Hodges has over eighteen years of biotech and information technology industry experience in the areas of finance, audit, strategy, corporate governance, facilities management, and public company preparedness and oversight. She began her career working in public accounting with Deloitte, Haskins and Sells, and as an entrepreneur, owned and operated a certified public accounting firm for over eight years. She is a member of the World at Work organization, American Institute of Certified Public Accountants and the North Carolina Association of Certified Public Accountants. Ms. Hodges received a B.S. in Business Administration and Accounting from Virginia Polytechnic Institute and State University.
Follow Hodges Mauri:
About Catalyst Biosciences: Catalyst Biosciences is a drug R&D company creating catalytic biopharmaceutical products based on engineered human proteases.
Hodges Mauri
Vice President, Finance and Administration, Chief Financial Officer and Treasurer of Catalyst Biosciences
Ms. Hodges joined Targacept in August 2000 and currently serves as Vice President, Finance and Administration, Chief Financial Officer and Treasurer. Ms. Hodges was previously Vice President, Human Resources and Corporate Systems and served as Controller for over thirteen years. Ms. Hodges has over eighteen years of biotech and information technology industry experience in the areas of finance, audit, strategy, corporate governance, facilities management, and public company preparedness and oversight. She began her career working in public accounting with Deloitte, Haskins and Sells, and as an entrepreneur, owned and operated a certified public accounting firm for over eight years. She is a member of the World at Work organization, American Institute of Certified Public Accountants and the North Carolina Association of Certified Public Accountants. Ms. Hodges received a B.S. in Business Administration and Accounting from Virginia Polytechnic Institute and State University.
Follow Hodges Mauri:
About Catalyst Biosciences: Catalyst Biosciences is a drug R&D company creating catalytic biopharmaceutical products based on engineered human proteases.
Keith Olivia
Vice President of Corperate Affairs and Genarl Counsel of OnKure
Keith Olivia is Board of Directors at Entrepreneurs Foundation of Colorado (EFCO).
Follow Keith Olivia:
About OnKure: OnKure is a biotechnology company that commercializes a new cancer therapy based on novel, less toxic kinase inhibitor drugs.
Karen Fritschen
EVP, Human Resources of ArcherDX
Karen Fritschen is the Executive Vice President of Human Resources at ArcherDX.
Follow Karen Fritschen:
About ArcherDX: ArcherDX is a biotechnology firm specializing in cancer research.
Suman Patel
Vice President of Manufacturing and Quality of Epirus Biopharmaceuticals
Follow Suman Patel:
About Epirus Biopharmaceuticals: Epirus Biopharmaceuticals develops biosimilar monoclonal antibodies and therapeutic proteins for emerging markets.
Michael Wyand
Senior Vice President of Clinical and Regulatory of Epirus Biopharmaceuticals
Follow Michael Wyand:
About Epirus Biopharmaceuticals, Oxeia Biopharmaceuticals: Epirus Biopharmaceuticals develops biosimilar monoclonal antibodies and therapeutic proteins for emerging markets.
Ellsworth Collins
Executive Vice President of Marketing of Advanced Solutions Life Sciences
Worth is an Executive Vice President of Marketing & Innovation for Advanced Solutions. In this capacity he leads a team of professionals dedicated to assisting companies improve their profitability through improvements in productivity, technology, quality, business processes, and customer satisfaction.
Follow Ellsworth Collins:
About Advanced Solutions Life Sciences: Advanced Solutions Life Sciences provides solutions for living organisms, molecular biology, and biotechnology.
Richard Lindahl
Executive Vice President & Chief Financial Officer of Emergent BioSolutions
Rich Lindahl currently serves as the executive vice president and chief financial officer at Emergent BioSolutions.
Follow Richard Lindahl:
About Corporate Executive Board (CEB), Emergent BioSolutions: Emergent BioSolutions develops, manufactures, and delivers a portfolio of medical countermeasures for biological and chemical threats.
Knud Mueller
Sr. Vice President & Chief Financial Officer of Beckman Coulter
Follow Knud Mueller:
About Beckman Coulter: Beckman Coulter develops, manufactures and markets products that simplify & automate biomedical testing for lab professionals.
Mario Koksch
Vice President , Flow Cytometry of Beckman Coulter
Follow Mario Koksch:
About Beckman Coulter: Beckman Coulter develops, manufactures and markets products that simplify & automate biomedical testing for lab professionals.
Ganesh Ramaswamy
Sr. Vice President , Customer Operations, Growth Markets of Beckman Coulter
Follow Ganesh Ramaswamy:
About Beckman Coulter: Beckman Coulter develops, manufactures and markets products that simplify & automate biomedical testing for lab professionals.
Steve C de Baca
Sr. Vice President , Quality & Regulatory Affairs of Beckman Coulter
Follow Steve C de Baca:
About Beckman Coulter: Beckman Coulter develops, manufactures and markets products that simplify & automate biomedical testing for lab professionals.
John Blackwood
Sr. Vice President , Chemistry & Immunoassay of Beckman Coulter
Follow John Blackwood:
About Beckman Coulter: Beckman Coulter develops, manufactures and markets products that simplify & automate biomedical testing for lab professionals.
Curt Brueske
Sr. Vice President, General Counsel of Beckman Coulter
Follow Curt Brueske:
About Beckman Coulter: Beckman Coulter develops, manufactures and markets products that simplify & automate biomedical testing for lab professionals.
Charles Purtell
Vice President , Strategy & Open Innovation of Beckman Coulter
Follow Charles Purtell:
About Beckman Coulter: Beckman Coulter develops, manufactures and markets products that simplify & automate biomedical testing for lab professionals.
Scott Strain
Vice President , Global Service of Beckman Coulter
Follow Scott Strain:
About Beckman Coulter: Beckman Coulter develops, manufactures and markets products that simplify & automate biomedical testing for lab professionals.
Maria Lopez
Vice President , Human Resources of Beckman Coulter
Follow Maria Lopez:
About Beckman Coulter: Beckman Coulter develops, manufactures and markets products that simplify & automate biomedical testing for lab professionals.
John Nosenzo
Sr. Vice President , Customer Operations Developed Markets of Beckman Coulter
Follow John Nosenzo:
About Beckman Coulter: Beckman Coulter develops, manufactures and markets products that simplify & automate biomedical testing for lab professionals.
Tim Kerr
Vice President , Research & Development of Beckman Coulter
Follow Tim Kerr:
About Beckman Coulter: Beckman Coulter develops, manufactures and markets products that simplify & automate biomedical testing for lab professionals.
Tim Kerr
Vice President , Research & Development of Beckman Coulter
Follow Tim Kerr:
About Beckman Coulter: Beckman Coulter develops, manufactures and markets products that simplify & automate biomedical testing for lab professionals.
John DelliSanti
Senior Vice President, Sales and Customer Service of Taconic Biosciences
Follow John DelliSanti:
About Taconic Biosciences: Taconic Biosciences engages in developing and delivering animal models and related laboratory services for the biomedical research
